首頁 > 市場調查報告書 > 工業機械

自動化

市場調查報告書

商品編碼

1637356

製藥協作機器人市場 - 全球產業規模、佔有率、趨勢、機會和預測，按應用、最終用途、地區和競爭細分，2020-2030F

Pharmaceutical Collaborative Robots Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By End-use, By Region & Competition, 2020-2030F

出版日期: 2025年01月17日 | 出版商:

TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年，全球製藥協作機器人市場估值為7,760 萬美元，預計到2030 年，預測期內將實現令人印象深刻的成長，複合年成長率為9.20%。標準的重要性強調了精準度在製造過程中的重要角色。協作機器人透過最大限度地減少錯誤和變化，同時透過一致和受控的流程提高產品質量，在實現合規性方面發揮關鍵作用。此外，熟練勞動力的稀缺和提高勞動力效率的願望推動了製藥協作機器人的採用，透過重複任務的自動化來簡化營運。這使得員工能夠將他們的專業知識集中在更有價值的任務上，最終提高整體生產力和營運效率。

市場概況
預測期	2026-2030
2024 年市場規模	7760萬美元
2030 年市場規模	13188萬美元
2025-2030 年複合年成長率	9.20%
成長最快的細分市場	揀選和包裝
最大的市場	北美洲

主要市場促進因素

提高產品品質

熟練勞動力短缺

勞動效率

營運效率

主要市場挑戰

實施成本

複雜的整合

主要市場趨勢

增強的安全功能

改善人機協作

細分市場洞察

應用洞察

區域洞察

Global Pharmaceutical Collaborative Robots Market was valued at USD 77.60 Million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 9.20% through 2030. In the pharmaceutical sector, the importance of adhering to regulations and maintaining high-quality standards highlights the essential role of precision in manufacturing procedures. Collaborative robots play a critical part in achieving compliance by minimizing mistakes and variations, while also enhancing product quality through consistent and controlled processes. Moreover, the scarcity of skilled labor and the desire to improve workforce efficiency drive the adoption of pharmaceutical collaborative robots, streamlining operations through the automation of repetitive tasks. This allows human employees to focus their expertise on more valuable tasks, ultimately increasing overall productivity and operational efficiency.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 77.60 Million
Market Size 2030	USD 131.88 Million
CAGR 2025-2030	9.20%
Fastest Growing Segment	Picking and Packaging
Largest Market	North America

Key Market Drivers

Improved Product Quality

The global pharmaceutical industry is renowned for its commitment to producing high-quality, safe, and effective medicines. Researchers identify one viable compound from a pool of 5,000 to 10,000 screened candidates. Following this, the compound undergoes extensive testing to assess its efficacy and safety, a rigorous process that typically spans 10 to 15 years for both pharmaceutical drugs and vaccines. In 2020, a total of 53 new medicines were launched into the market, while over 9,000 compounds are currently in various stages of development worldwide, reflecting the ongoing and extensive pipeline of potential treatments and vaccines in progress. Regulatory agencies, such as the FDA and EMA, enforce stringent standards to ensure the quality of pharmaceutical products. In this context, the utilization of collaborative robots, or "cobots," has gained significant traction. These robots are not just automating processes; they are also contributing to a critical factor that drives growth in the pharmaceutical industry-improved product quality.

One of the primary reasons pharmaceutical manufacturers are turning to collaborative robots is their ability to significantly reduce errors. Globally, the annual cost of medication errors is estimated at approximately USD42 billion. These errors can arise at various stages of the medication use process. Factors such as inadequate medication systems, human errors-often influenced by fatigue, poor working conditions, or staffing shortages-can negatively impact prescribing, transcribing, dispensing, administration, and monitoring. These lapses in the medication management process can lead to significant patient harm, including severe disability or even death. Cobots are programmed to execute tasks with precision, leaving little to no room for human errors. Whether it's dispensing, packaging, or inspecting pharmaceutical products, cobots consistently perform these tasks, minimizing defects and ensuring product integrity. Fewer errors lead to fewer product recalls and regulatory violations, which in turn enhances the reputation of pharmaceutical companies.

Collaborative robots excel in maintaining a high degree of consistency in manufacturing processes. They are not affected by factors like fatigue or distractions, which can influence human operators. This consistency results in pharmaceutical products that are not only uniform in quality but also meet regulatory standards on a consistent basis.

Pharmaceutical manufacturers are under constant scrutiny to adhere to rigorous regulatory standards. ISO 9001: ISO 9001 is the globally recognized standard for quality management systems, offering a structured framework and set of principles designed to enhance organizational performance and consistency. ISO 13485: ISO 13485 specifically addresses the quality management requirements for the design, production, and servicing of medical devices. Collaborative robots, equipped with the necessary sensors and automation technology, ensure compliance with these standards. They can precisely follow Good Manufacturing Practices (GMP) and Good Automated Manufacturing Practices (GAMP) guidelines, reducing the likelihood of regulatory violations and costly consequences.

Pharmaceutical products are highly sensitive to contamination. Collaborative robots, operating in controlled environments, minimize the risk of contamination associated with human contact. They are sterilizable, reducing the chances of introducing foreign particles or microbes into the manufacturing process. This not only improves product quality but also upholds patient safety.

Collaborative robots can be equipped with advanced vision systems that can perform meticulous inspections at a level of detail that may be challenging for human operators. They can identify imperfections, irregularities, and inconsistencies that might go unnoticed by the human eye. By detecting these issues early in the production process, cobots contribute to the delivery of pharmaceutical products of the highest quality.

Improved product quality translates into cost savings for pharmaceutical manufacturers. Reduced waste due to fewer defects and errors means less material and product wastage. This is a significant financial benefit that boosts the bottom line for pharmaceutical companies, making the investment in collaborative robots a financially sound decision.

Skilled Labor Shortages

The pharmaceutical industry is experiencing a period of remarkable growth and innovation, driven by an increased demand for medicines and a growing aging population. However, this surge in demand has coincided with a significant challenge: a shortage of skilled labor. To address this issue, pharmaceutical manufacturers are increasingly turning to collaborative robots, or "cobots," to fill the workforce gap. In the biopharmaceutical sector, there are currently over 800,000 employees, but more than 60,000 job vacancies highlight a labor shortage of approximately 8%. Looking ahead, job opportunities within the life, physical, and social sciences sectors are expected to grow by 7% by 2028, outpacing growth in other industries.

The pharmaceutical industry is expanding rapidly, particularly with the emergence of new drug therapies and the need for vaccine production. The pharmaceutical industry is on the verge of significant breakthroughs in drug discovery, fueled by an impressive USD230 billion investment in research and development in 2021. This represents a consistent annual growth rate of 7% since 2015. As a result, the pipeline of products across various stages of development has reached unprecedented levels, while concurrent advancements in technology are enabling the generation of highly detailed, accurate, and actionable insights. This growth has outpaced the ability to train and hire skilled professionals. Many skilled pharmaceutical workers are nearing retirement, leading to a generational shift in the workforce. The loss of experienced professionals creates a vacuum that is challenging to fill. The pharmaceutical industry requires specialized knowledge in areas such as pharmaceutical engineering, quality control, and regulatory compliance. Acquiring this expertise takes time, which is often in short supply. The pharmaceutical sector operates under strict regulatory regimes, necessitating a workforce that is well-versed in compliance with Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).

Collaborative robots can handle repetitive, mundane tasks, allowing the available skilled workforce to focus on higher-value, specialized work. This enables a more efficient use of existing skilled labor resources. Cobots are programmed to execute tasks with precision and consistency, reducing the risk of errors and variations that can occur when human operators are overburdened or inexperienced. Collaborative robots can operate continuously, which is particularly useful in the pharmaceutical industry, where certain processes need to run around the clock. This mitigates the challenges posed by limited work shifts and worker fatigue. By taking over repetitive and physically demanding tasks, collaborative robots relieve human workers from these burdens. This, in turn, improves overall workforce efficiency and job satisfaction. Cobots are designed to be user-friendly, with programming that can be easily learned by existing employees. This means that pharmaceutical companies can quickly integrate these robots into their operations. While the initial investment in cobots is significant, the long-term cost savings from reduced labor needs, improved product quality, and increased operational efficiency make them a cost-effective solution.

Workforce Efficiency

The pharmaceutical industry is a dynamic and highly regulated sector that demands precision, quality, and efficiency. However, maintaining workforce efficiency while adhering to strict regulatory requirements can be a daunting task. In recent years, the global pharmaceutical collaborative robots market has seen substantial growth, largely driven by the need to enhance workforce efficiency. Currently, approximately 50% of tasks within the pharmaceutical and medical manufacturing industries have the potential to be automated. In the next decade, over 90,000 jobs could be eliminated, while 90,000 to 120,000 new roles may emerge. Pharmaceutical executives anticipate a 27% annual increase in the proportion of jobs impacted by automation over the next ten years.

Stringent regulatory requirements necessitate meticulous documentation, quality control, and adherence to Good Manufacturing Practices (GMP). This places a significant administrative burden on the workforce. The pharmaceutical industry requires a skilled workforce with expertise in areas such as laboratory analysis, quality assurance, and regulatory affairs. However, the shortage of such skilled labor poses a significant challenge. The global demand for pharmaceutical products, including vaccines and innovative therapies, has surged. Meeting this demand while maintaining workforce efficiency is a complex endeavor. Pharmaceuticals must be produced with a high degree of safety and quality. Ensuring these standards is labor-intensive, and any compromise in these areas can have dire consequences.

Cobots excel at performing routine, repetitive tasks, such as labeling, packaging, and material handling. Collaborative robots (cobots), designed to work safely alongside human operators, are becoming increasingly prevalent in industrial environments. According to ISO 10218 Parts 1 and 2, cobots are classified into four distinct types, each incorporating various safety features such as monitored stop, speed and separation control, power and force limiting, and hand guiding. These safety protocols are essential for ensuring that cobots can perform their tasks effectively while maintaining a safe working environment for human workers. This automation relieves human workers from monotonous duties, enabling them to focus on higher-value, intellectually demanding tasks. Collaborative robots are programmed to execute tasks with precision and consistency. They do not suffer from fatigue or distractions and can work around the clock, ensuring a consistently high level of performance. The risk of errors and inconsistencies in pharmaceutical manufacturing is significantly reduced with cobots. These robots can perform tasks with minimal deviations, leading to fewer product defects and regulatory violations. Collaborative robots can be equipped with advanced vision systems that can inspect pharmaceutical products with great detail and accuracy. This ensures that products meet the highest quality standards. Cobots enhance workforce efficiency by enabling human workers to allocate their skills to more critical, non-repetitive tasks. This not only increases job satisfaction but also ensures that the right tasks are performed by the right personnel. The integration of cobots leads to cost savings by reducing labor needs and improving operational efficiency. The initial investment in these robots is offset by long-term gains in productivity and product quality.

Operational Effectiveness

The pharmaceutical sector operates under strict regulatory guidelines and quality standards, necessitating meticulous documentation and adherence to Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP). The production of pharmaceuticals involves intricate processes, including synthesis, formulation, packaging, and quality control, each with unique demands for precision and consistency. The industry grapples with a shortage of skilled labor, which is essential for tasks requiring expertise in laboratory analysis, quality assurance, and regulatory compliance. Certain pharmaceutical processes must operate continuously, necessitating a workforce that can handle 24/7 production.

Cobots are programmed to perform tasks with a high degree of precision and accuracy. They minimize errors, reducing defects in pharmaceutical products and minimizing the risk of costly regulatory violations. Cobots work tirelessly without experiencing fatigue or distractions, ensuring a consistent level of performance. This consistency is essential in pharmaceutical manufacturing to meet quality and regulatory standards. Cobots can be programmed to strictly adhere to regulatory requirements, such as GMP and GLP. Their documentation and data collection capabilities help streamline compliance efforts. The pharmaceutical industry requires a sterile environment. Cobots can operate in cleanrooms and controlled environments, reducing the risk of contamination associated with human workers. Collaborative robots can be equipped with advanced vision systems for meticulous inspection. They can detect imperfections and deviations in products, contributing to the delivery of pharmaceuticals of the highest quality. Cobots can operate around the clock, ensuring continuous production. This is especially important in pharmaceutical processes that cannot afford downtime.

Key Market Challenges

Cost of Implementation

While collaborative robots offer long-term cost savings, the initial investment can be substantial. Purchasing, integrating, and programming cobots can represent a significant financial commitment for pharmaceutical manufacturers. Smaller companies or those with limited budgets may find it challenging to make this initial investment in automation technology.

Complex Integration

Integrating collaborative robots into existing pharmaceutical manufacturing processes can be a complex endeavor. Each pharmaceutical facility has its unique workflow, machinery, and safety protocols. Ensuring that cobots seamlessly fit into these processes while adhering to safety standards requires careful planning and expertise.

Key Market Trends

Enhanced Safety Features

Safety has always been a top priority in the pharmaceutical industry. Upcoming trends in collaborative robots include the integration of advanced safety features. These robots will have improved sensors and vision systems to avoid collisions with humans and other equipment. Compliance with rigorous safety standards, such as ISO 13849 and ISO 10218, will continue to be a focus.

Improved Human-Robot Collaboration

Pharmaceutical manufacturers are increasingly looking for ways to enhance the synergy between human workers and robots. This involves developing more intuitive interfaces and ergonomic designs, making it easier for employees to collaborate with cobots. Improved collaboration will lead to a smoother workflow, higher job satisfaction, and overall operational efficiency.

Segmental Insights

Application Insights

Based on the category of Application, the picking and packaging sector asserted its supremacy in the market by securing the largest market share in 2024. This achievement can be attributed to the pivotal role this segment plays in the supply chain and manufacturing processes. Picking and packaging operations are instrumental in efficiently organizing, preparing, and dispatching products. Given the rising demand for streamlined logistics, the rapid growth of e-commerce, and the necessity for precision in delivering products to consumers, companies are giving high priority to automation solutions in these areas.

Consequently, investments in collaborative robots for picking and packaging have witnessed a remarkable surge, strengthening the segment's dominance in the 2024 market. Moreover, this segment is anticipated to experience the swiftest growth with a CAGR during the forecast period. This growth can be attributed to the capability of robots to enhance precision and efficiency while addressing complex material handling challenges. Furthermore, the pick-and-place approach offers these advantages while conserving floor space by operating within a limited work area, effectively optimizing workspace utilization. This trend reflects the industry's commitment to maximizing operational efficiency while ensuring efficient use of available space.

Regional Insights

In 2024, the North America region held the largest market share and is expected to experience substantial growth in the forecasted period. North America, particularly the United States, is a global leader in technological innovation. The region boasts a well-established ecosystem for research and development, particularly in robotics and automation technologies. Pharmaceutical companies in the U.S. and Canada are leveraging collaborative robots to enhance production efficiency, precision, and safety in drug manufacturing. Cobots are increasingly being adopted for tasks such as packaging, labeling, quality control, and drug inspection, where automation can reduce human error and increase throughput. The continuous advancements in AI, machine learning, and sensor technologies in North America further boost the capabilities of cobots, making them increasingly viable in pharmaceutical applications.

North America is home to some of the largest pharmaceutical companies in the world. U.S.-based contract manufacturing specialist, utilized a UR10 collaborative robot (cobot) equipped with a vision system to perform engine inspection tasks. This implementation led to enhanced throughput and improved product quality. In addition, cobots are increasingly being used for Pick & Place operations, such as adding components to products during assembly, packing completed products into boxes, and stacking pallets. These tasks benefit from cobots' precision and efficiency, driving operational improvements in manufacturing processes. These companies are at the forefront of adopting cutting-edge technologies, including collaborative robots, to streamline production processes and meet the growing demand for pharmaceuticals. The need for precision, cost-effectiveness, and compliance with stringent regulatory standards drives the demand for automation solutions in the pharmaceutical manufacturing process. Cobots, known for their flexibility and ability to work alongside human operators, are ideal for improving productivity without sacrificing the quality or safety standards required in drug production.

North America has well-established regulatory frameworks, such as the U.S. Food and Drug Administration (FDA) and Health Canada, that ensure high standards of safety, quality, and efficiency in pharmaceutical manufacturing. These regulations often drive pharmaceutical companies to adopt advanced technologies to meet compliance requirements. Collaborative robots are seen as an effective tool in maintaining the consistency and accuracy needed in pharmaceutical production, particularly when it comes to meeting Good Manufacturing Practices (GMP) and other stringent regulatory standards. The ability of cobots to operate in a controlled and compliant manner enhances their adoption within North American pharmaceutical companies.

Key Market Players

ABB Limited
Universal Robots A/S
Mitsubishi Electric Corp
KUKA AG
Kawasaki Heavy Industries Ltd
YASKAWA Electric Corporation
Denso Wave Inc
Fanuc America Corp

Report Scope:

In this report, the Global Pharmaceutical Collaborative Robots Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical Collaborative Robots Market, By Application:

Picking and Packaging
Inspection of Pharmaceutical Drugs
Laboratory Applications

Pharmaceutical Collaborative Robots Market, By End-use:

Pharmaceutical Companies
Research Laboratories
Others

Pharmaceutical Collaborative Robots Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical Collaborative Robots Market.

Available Customizations:

Global Pharmaceutical Collaborative Robots market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharmaceutical Collaborative Robots Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Application (Picking and Packaging, Inspection of Pharmaceutical Drugs, Laboratory Applications)
- 5.2.2. By End-use (Pharmaceutical Companies, Research Laboratories, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Product Market Map
- 5.3.1. By Application
- 5.3.2. By End-use
- 5.3.3. By Region

6. North America Pharmaceutical Collaborative Robots Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Application
- 6.2.2. By End-use
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Pharmaceutical Collaborative Robots Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Application
    - 6.3.1.2.2. By End-use
- 6.3.2. Canada Pharmaceutical Collaborative Robots Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Application
    - 6.3.2.2.2. By End-use
- 6.3.3. Mexico Pharmaceutical Collaborative Robots Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Application
    - 6.3.3.2.2. By End-use

7. Europe Pharmaceutical Collaborative Robots Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Application
- 7.2.2. By End-use
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Pharmaceutical Collaborative Robots Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Application
    - 7.3.1.2.2. By End-use
- 7.3.2. United Kingdom Pharmaceutical Collaborative Robots Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Application
    - 7.3.2.2.2. By End-use
- 7.3.3. France Pharmaceutical Collaborative Robots Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Application
    - 7.3.3.2.2. By End-use
- 7.3.4. Italy Pharmaceutical Collaborative Robots Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Application
    - 7.3.4.2.2. By End-use
- 7.3.5. Spain Pharmaceutical Collaborative Robots Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Application
    - 7.3.5.2.2. By End-use

8. Asia-Pacific Pharmaceutical Collaborative Robots Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Application
- 8.2.2. By End-use
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Pharmaceutical Collaborative Robots Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Application
    - 8.3.1.2.2. By End-use
- 8.3.2. Japan Pharmaceutical Collaborative Robots Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Application
    - 8.3.2.2.2. By End-use
- 8.3.3. India Pharmaceutical Collaborative Robots Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Application
    - 8.3.3.2.2. By End-use
- 8.3.4. Australia Pharmaceutical Collaborative Robots Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Application
    - 8.3.4.2.2. By End-use
- 8.3.5. South Korea Pharmaceutical Collaborative Robots Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Application
    - 8.3.5.2.2. By End-use

9. South America Pharmaceutical Collaborative Robots Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Application
- 9.2.2. By End-use
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Pharmaceutical Collaborative Robots Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Application
    - 9.3.1.2.2. By End-use
- 9.3.2. Argentina Pharmaceutical Collaborative Robots Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Application
    - 9.3.2.2.2. By End-use
- 9.3.3. Colombia Pharmaceutical Collaborative Robots Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Application
    - 9.3.3.2.2. By End-use

10. Middle East and Africa Pharmaceutical Collaborative Robots Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Application
- 10.2.2. By End-use
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Pharmaceutical Collaborative Robots Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Application
    - 10.3.1.2.2. By End-use
- 10.3.2. Saudi Arabia Pharmaceutical Collaborative Robots Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Application
    - 10.3.2.2.2. By End-use
- 10.3.3. UAE Pharmaceutical Collaborative Robots Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Application
    - 10.3.3.2.2. By End-use
- 10.3.4. Kuwait Pharmaceutical Collaborative Robots Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Application
    - 10.3.4.2.2. By End-use

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. ABB Limited
- 14.1.1. Business Overview
- 14.1.2. Product Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (As Reported)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
14.2. Universal Robots A/S
14.3. Mitsubishi Electric Corp
14.4. KUKA AG
14.5. Kawasaki Heavy Industries Ltd
14.6. YASKAWA Electric Corporation
14.7. Denso Wave Inc
14.8. Fanuc America Corp